863888-29-3

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 102229-10-7 2-(tert-butyldimethylsilyloxy)ethanol 
• 58334-93-3 4-(2-hydroxyethoxymethyl)benzoic acid methyl ester 
• 6908-41-4 4-(methoxycarbonyl)benzyl alcohol 
• 863888-28-2 4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]-benzoic acid methyl ester 

Downstream Products

• 863888-31-7 2-(tert-butyl)-4-chloro-5-((4-((2-hydroxyethoxy)methyl)benzyl)oxy)pyridazin-3(2H)-one 
• 863888-32-8 toluene 4-sulfonic acid 2-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-benzyloxy]-ethyl ester 
• 863887-89-2 (2-tert-butyl-4-chloro-5-(4-2-(¹⁸F)fluoroethoxymethyl)-benzyloxy)-2H-pyridazin-3-one 
• 863888-30-6 2-tert-butyl-5-{4-[2-(tert-butyldimethylsilanyloxy)-ethoxymethyl]benzyloxy}-4-chloro-3-(2H)-pyridazinone 

Relevant academic research and scientific papers

[18F]Flurpiridaz: Facile and Improved Precursor Synthesis for this Next-Generation Cardiac Positron Emission Tomography Imaging Agent

[18F]Flurpiridaz is a recently developed positron emission tomography tracer that is currently being investigated in phase III clinical trials to measure myocardial blood flow. The relatively long physical half-life of fluorine-18 alongside the

Contrast agents for applications including perfusion imaging

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF

The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comp

Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers

A series of fluorinated pyridazinone derivatives with IC50 values ranging from 8 to 4000 nM for the mitochondrial complex 1 (MC1) have been prepared. Structure-activity relationship (SAR) assessment indicated preference of the fluorine label to be incorporated on an alkyl side chain rather than directly on the pyridazinone moiety. Tissue distribution studies of a series of analogues ([18F] 22-28) in Sprague-Dawley (SD) rats identified [ 18F]27 as the most promising radiotracer with high uptake in cardiac tissue (3.41%ID/g; 30 min post injection) in addition to favorable heart to nontarget organ distribution ratios. MicroPET images of SD rats and nonhuman primates after [18F]27 administration allowed easy assessment of the myocardium through 60 min with minimal lung or liver interference.

Contrast agents for myocardial perfusion imaging

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.